Russia's 'Sputnik V' COVID-19 vaccine shows over 91.4% efficacy as per interim trial data

world’s first COVID-19 vaccine to be registered, Russia’s Sputnik V, has anunced its efficacy to be 91.4% based on interim analysis of data gleaned from a st-3 clinical trial involving 40,000 people in Russia. After Pfizer-BioNTech declared its vaccine to be 95% effective and Moderna’s vaccine's efficacy was determined to be 94.5% in early trials, Russia’s Sputnik V anuncement on vember 24 also came hot on heels of  Oxford University-AstraZeneca vaccine's overall efficacy being pegged at 70.4%. 

Moreover, preliminary data obtained by volunteers 42 days after first dose that corresponds with 21 days after second dose indicates that efficacy of vaccine above 95%. official statement also said that interim research will be published by Gamaleya Center team in one of leing international peer-reviewed medical journals after completion of Phase III clinical trials of Sputnik V vaccine. As of w, at least 40,000 volunteers are taking part in clinical trials, out of which, 22,000 volunteers were vaccinated with first dose and more than 19,000 volunteers with first and second doses with verse events being recorded. 

official statement said, “ efficacy of Sputnik V vaccine is 91.4%, based on second interim analysis of data obtained 28 days after ministering first dose (7 days after second dose).”

“Preliminary data from volunteers obtained 42 days after first dose (corresponds with 21 days after second dose) indicates an efficacy of vaccine above 95%,” it ded.

Re - Karnataka Is Well Prepared For COVID-19 Vaccine Delivery: Sudhakar

Re - COVID-19: Poorest Must t Be 'trampled' In 'stampede For Vaccine', Says WHO Chief

Russia hails efficacy as ‘most important tool’

After facing criticism initially for racing through medical research for sake of gaining an upper hand amid global competition, Russian government hailed vember 24 anuncement as “most important tool” in fight against COVID-19 pandemic. Russia’s health minister Mikhail Murashko said that “ data demonstrating high efficacy of Sputnik V vaccine gives us hope that we will soon obtain most important tool in fight against pandemic of vel coronavirus infection.”

In ar “important milestone” in world’s fight against pandemic, Oxford University has anunced on vember 23 that its COVID-19 vaccine candidate developed in collaboration with AstraZeneca is 70.4% effective against highly-infectious disease. A tentative vant for Oxford and AstraZeneca’s vaccine is that it's far cheaper and comparatively easier to store and transport to even remote areas of world. 

Re - UK Govt Welcomes Oxford Covid Vaccine Results; Health Secy Sees rmalcy By April 2021

Re - Asian Shares Mostly Rise On Virus Vaccine, Yellen Hopes